Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Webinar: Gastric Cancer

Aired live on 23 Nov 2021


ESMO Webinar: Gastric Cancer

Chair: Ian Chau
Speakers: Markus Moehler, Hanneke van Laarhoven, Takako Nakajima

Optimising sequential therapy in advanced gastric/GEJ cancer: the importance of appropriate treatment selection to improve treatment outcomes

Login to get immediate access to this content.


In this webinar, the panel reviewed and discussed incorporation of immune checkpoint inhibitors in both first-line treatment for advanced disease and in the adjuvant setting, their impact on subsequent treatment, the current status of targeted therapy and the testing of biomarkers and upcoming combination treatment strategies in patients with gastric/GEJ cancer.

Learning objectives

  • To understand the current paradigm of incorporating checkpoint inhibitors both in the first line advanced disease and post-operative adjuvant settings and its impact on subsequent treatment in gastric/GEJ adenocarcinoma
  • To review the current status of HER2 and other targeted therapy and understand when and how to test for these biomarkers in the patient’s treatment pathway
  • To appreciate the upcoming strategies of improving on immunotherapy in gastric cancer
  • To review the above objectives via a short clinical cased discussion as well as audience Q&A session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.